Update on biologics in juvenile idiopathic arthritis

Norman T. Ilowite

doi:10.1097/BOR.0b013e3283060778

Update on biologics in juvenile idiopathic arthritis

Norman T. Ilowite

Pediatrics

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

Original language	English (US)
Pages (from-to)	613-618
Number of pages	6
Journal	Current opinion in rheumatology
Volume	20
Issue number	5
DOIs	https://doi.org/10.1097/BOR.0b013e3283060778
State	Published - Sep 1 2008

Keywords

Interleukin-1
Interleukin-6
Juvenile idiopathic arthritis
Tumor necrosis tor
Uveitis

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1097/BOR.0b013e3283060778

Cite this

@article{defe317835cb4ce79d3bbf3155e20d45,

title = "Update on biologics in juvenile idiopathic arthritis",

abstract = "As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.",

keywords = "Interleukin-1, Interleukin-6, Juvenile idiopathic arthritis, Tumor necrosis tor, Uveitis",

author = "Ilowite, {Norman T.}",

year = "2008",

month = sep,

day = "1",

doi = "10.1097/BOR.0b013e3283060778",

language = "English (US)",

volume = "20",

pages = "613--618",

journal = "Current Opinion in Rheumatology",

issn = "1040-8711",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Update on biologics in juvenile idiopathic arthritis

AU - Ilowite, Norman T.

PY - 2008/9/1

Y1 - 2008/9/1

N2 - As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

AB - As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

KW - Interleukin-1

KW - Interleukin-6

KW - Juvenile idiopathic arthritis

KW - Tumor necrosis tor

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=55249084910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249084910&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e3283060778

DO - 10.1097/BOR.0b013e3283060778

M3 - Review article

C2 - 18698187

AN - SCOPUS:55249084910

SN - 1040-8711

VL - 20

SP - 613

EP - 618

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

IS - 5

ER -

Update on biologics in juvenile idiopathic arthritis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this